Ctdna Status Flags Early Prostate Cancer Progression Risk

A phase 2 trial links pre-radiotherapy ctDNA detection to shorter progression-free survival in oligoprogressive prostate cancer patients.

Updated on Nov. 18, 2026 in Cancer

Clear plastic tubes of pale amber liquid rest on a steel laboratory bench in front of a softly blurred sequencing instrument.
A phase 2 trial found that detecting circulating tumor DNA before stereotactic radiotherapy was linked to progression-free survival of 3.0 months versus 7.8 months in oligoprogressive prostate cancer patients. AI Illustration. Upload story photo >

Researchers found that detecting circulating tumor DNA before stereotactic body radiotherapy was associated with shorter progression-free survival in patients with oligoprogressive castration-resistant prostate cancer who continued androgen receptor pathway inhibitor therapy. Median progression-free survival was 3.0 months in ctDNA-positive patients versus 7.8 months in ctDNA-negative patients.

Why it matters

The findings suggest that ctDNA testing could help identify patients whose disease is more likely to progress early, potentially informing treatment decisions for men with advanced prostate cancer. The investigators proposed that earlier relapse in ctDNA-positive patients may reflect active metastases missed by imaging.

The phase 2 TRAP trial found median progression-free survival of 3.0 months in ctDNA-positive patients versus 7.8 months in ctDNA-negative patients among 77 evaluable patients, with ctDNA positivity the only variable associated with PFS in a multivariable model (adjusted HR, 2.18; P = 0.009). Whether these associations hold in randomized trials remains unknown, as the study was single-arm and nonrandomized.

The players

The Royal Marsden NHS Foundation Trust

The Royal Marsden is a specialist cancer centre in London and one of the largest cancer hospitals in Europe, and it sponsored the TRAP trial.

University College London (UCL) Cancer Institute

The UCL Cancer Institute is a leading research institute in London whose affiliated investigators contributed to the study.

The details

Patients with rising PSA after at least six months of abiraterone or enzalutamide and no more than two progressing metastases received stereotactic body radiotherapy at 30 Gy in five fractions while continuing their hormone therapy. Plasma was centrally tested with the PCF_SELECT next-generation sequencing assay, which detects tumor-specific copy number changes.

Timeline

  1. October 2018 to February 2023: Patient enrollment period for the TRAP trial.

  2. 2026: Secondary analysis published in JAMA Network Open.

Health Landscape

The TRAP results extend efforts to use liquid biopsy biomarkers to guide metastasis-directed therapy in advanced prostate cancer, a field where imaging alone has struggled to detect micrometastatic disease. The findings add to a growing body of evidence that ctDNA may refine risk stratification for men with castration-resistant disease.

For men with advanced prostate cancer, the findings suggest that a blood test for ctDNA could eventually help clinicians judge how likely disease is to progress while on hormone therapy. The results are early, however, and the test is not yet a standard part of care for patients considering radiotherapy.

The takeaway

Pre-treatment ctDNA may offer an early signal of how a prostate cancer patient's disease will behave, but confirmation in randomized studies is needed before it guides care. Patients should discuss any biomarker testing with their oncology team.

Further reading

Explore more on Cancer research and treatment developments.

Source note: This article includes information reported by Cancernetwork.